目的 探讨达依泊汀α用于治疗血液透析贫血的疗效以及对血红蛋白变异幅度的影响。方法 选取合肥金楠肾病专科医院2022年8月—2023年9月的维持性血液透析患者38人，随机分为2组。观察组给予达依泊汀α治疗，对照组给予短效红细胞生成素治疗。研究分为治疗矫正期和治疗维持期，每月定期检测血红蛋白、生化及第0、第5个月的铁代谢情况等指标。比较2组治疗前后血红蛋白水平，分析血红蛋白水平变化趋势，并统计不良事件。 结果 观察组(n=17)和对照组(n=19)患者治疗前血红蛋白比较差异无统计学意义(t=0.174，P=0.863)，治疗结束后2组血红蛋白水平差异无统计学意义(t=0.809，P=0.425)。2组不良事件发生率差异无统计学意义(心力衰竭事件、内瘘闭塞均P=1.000)。治疗矫正期观察组的血红蛋白上升更明显且更稳定(F=3.624，P=0.034)。 结论 达依泊汀α具有和短效红细胞生成素相当的安全性和治疗效果，并且能够维持血红蛋白水平的稳定增长，降低血红蛋白的变异幅度。
Objective To investigate the efficacy of darbepoetin alfa for the treatment of anemia and its effect on hemoglobin variation in hemodialysis patients. Methods A total of 38 stable hemodialysis patients treated in Hefei Jin'nan Kidney Disease Specialized Hospital from August 2022 to September 2023 were selected and randomly divided into two groups, observation group (n=19; 2 dropped out) received darbepoetin alfa treatment, and control group (n=19) received conventional short-acting erythropoiesis stimulating agent treatment. The study consisted of a correction phase and a maintenance phase, with assays of hemoglobin and biochemical indicators monthly, and iron metabolism indicators at 0 and 5th months. Independent samples t-test was used to compare hemoglobin levels before and after treatment between the two groups. Paired t-test was used for before-after self-control comparisons in each group. Repeated measures analysis was performed to examine the trend of hemoglobin change in both groups over time. Chi-square test was used for adverse event analysis. Results There was no significant difference in pretreatment hemoglobin level between the two groups (t=0.174, P=0.863). Post-treatment hemoglobin level also had no significant difference (t=0.809, P=0.425). No significant differences in adverse events (heart failure events, P=1.000; fistula occlusion, P=1.000) were found between the two groups. During the correction phase, the observation group showed a more pronounced and stable hemoglobin increase (F=3.624, P=0.034). Conclusion Darbepoetin alfa has the safety and efficacy comparable to those of short-acting erythropoiesis stimulating agents, and can maintain hemoglobin at a stable increase level with less variability.
[1]李菲,魏日胞.促红细胞生成素产生细胞与慢性肾脏病贫血及肾纤维化关系的研究进展[J].解放军医学杂志,2020,45(06):680-684.
[2]孙雪峰.慢性肾脏病合并肾性贫血的处理策略[J].中国实用内科杂志,2010,30(02):106-108.
[3]Robles NR, Garcia de Vinuesa E. Renal anemia: Hypoxia inducible factor stabilizers. Med Clin (Barc). 2023 Jan 20;160(2):82-84. English, Spanish.?
[4]Allison SJ. Anaemia: Targeting epigenetics in renal anaemia. Nat Rev Nephrol. 2016 Mar;12(3):125.?
[5]Yang SH, Yang SI, Chung YK. A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9.?
[6]Dwitanto K, Angginy N, Sutandar W. Comparative Study of Recombinant Human Erythropoietin (rhEPO) Products on CKD (Chronic Kidney Disease) Patients. Drug Res (Stuttg). 2023 Jun;73(5):271-278.?
[7]Le?ai? V, Petkovi? N, Mari? I, et al.The pharmacokinetics of recombinant human erythropoietin in Balkan endemic nephropathy patients. Nefrologia. 2013;33(4):478-85. English, Spanish.?
[8]Coyne DW, Singh AK, Lopes RD, et al. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 Sep;17(9):1325-1336.?
[9]De Meester J, Maes B, De Vriese A, et al. Fluctuations of haemoglobinaemia in chronic haemodialysis patients. Acta Clin Belg. 2011 Mar-Apr;66(2):123-8.
[10]Wilhelm-Leen ER, Winkelmayer WC. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul;66(1):69-74.?
[11]中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志,2021,101(20)：1463-1502.
[12]Sinha SD, Bandi VK, Bheemareddy BR, et al.Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial. BMC Nephrol. 2019 Mar 13;20(1):90.
[13]肖成根,徐丽霞,陶一鸣等.长短效红细胞生成素在维持性血液透析患者中应用的临床观察[J].中国血液净化,2014,13(01):1-4+48.
[14]Prakash D. Anemia in the ICU: anemia of chronic disease versus anemia of acute illness. Crit Care Clin. 2012 Jul;28(3):333-43, v.?
[15]Al-Ageel NA, Al-Aqeel SA, Abanmy NO, et al.Appropriateness of anemia management in hemodialysis patients. Saudi Pharm J. 2012 Jan;20(1):85-91.?
[16]Milojkovic R. A heightened awareness: hemoglobin variants and HbA1c. MLO Med Lab Obs. 2013 May;45(5):50, 52, 54. PMID: 23763051.
[17]刘爱春,韦洮.长效红细[17]胞生成素的研究和应用进展[J].中国血液净化,2023,22(03):161-163.
[18]Uemura O, Hattori M, Hataya H, et al.Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. Clin Exp Nephrol. 2014 Dec;18(6):932-8.?
[19]olman C, Richardson D, Bartlett C, et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol. 2005 May;16(5):1463-70.
[20]王春花,胡文博,王宁宁等.单中心慢性肾脏病3～5期患者肾性贫血的相关因素分析[J].中国现代医学杂志,2023,33(24):1-6.
